Article

Potential cost-effectiveness of individualized medicine in prodromal Alzheimer’s disease by demographic, clinical and cerebrospinal fluid proteomics factors

2023-01-28

Abstract excerpt

<h4>ABSTRACT</h4> <h4>INTRODUCTION</h4> Three distinct pathophysiological subtypes of Alzheimer’s disease (AD) have been identified based on CSF proteomics. We aim to estimate the potential incremental cost-effectiveness ratio of individualized hypothetical AD pharmacological treatment through stratification by these subtypes. <h4>METHODS</h4> In a model-based health-economic evaluation usual care was compared to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4958c8e3-c130-56f6-987d-6b1430f616d2
DOI: 10.1101/2023.01.24.23284478

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 11 closest

Potential cost-effectiveness of individualized medicine in prodromal Alzheimer’s disease by demographic, clinical and cerebrospinal fluid proteomics factorsDOI 10.1101/2023.01.24.23284478Read

Associations of Alzheimer’s disease with inpatient hospital costs and with quality-adjusted life years: Evidence from conventional and Mendelian randomization analyses in the UK BiobankSemantic proximity Read

Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled TrialSemantic proximity Read

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseSemantic proximity Read

Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 TreatmentSemantic proximity Read

Use of preclinical Alzheimer’s disease trajectories for clinical trial designSemantic proximity Read

When algorithms replace biologists: A Discrete Choice Experiment for the valuation of risk-prediction tools in Neurodegenerative DiseasesSemantic proximity Read

Cost-effectiveness of dementia insurance for cognitively-unimpaired<i>APOE-ε4</i>homozygotes – a simulation studySemantic proximity Read

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's diseaseSemantic proximity Read

Mapping U.S. POINTER Cognitive-Slope Gains Onto Predicted Clinical Progression: An External-Cohort Translation Analysis With Exploratory Economic ThresholdsSemantic proximity Read

A quantitative model of human neurodegenerative diseases involving protein aggregationSemantic proximity Read